Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ziopharm Oncology Announces Election of Robert Postma to its Board of Directors
BOSTON , Feb. 05, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the election of Robert Postma to its Board of Directors (the “Board”), effective immediately. Mr. Postma is the Founder of WaterMill Asset Management, a sizeable and
View HTML
Toggle Summary Ziopharm Oncology Announces Election of James Huang as Chairman of the Board of Directors
– Mr. Huang is a veteran industry entrepreneur with 20+ years founding and funding biotech innovation – – Heidi Hagen elected Lead Independent Director – BOSTON , Jan. 14, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP) today announced the election of
View HTML
Toggle Summary Ziopharm to Participate in Upcoming January Conferences
BOSTON , Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the H.C.
View HTML
Toggle Summary Ziopharm Oncology Announces Clearance of Taiwan’s First IND of Non-viral CAR-T for the Treatment of Relapsed CD19+ Leukemias and Lymphomas
– Advances Eden BioCell’s clinical program to validate Rapid Personalized Manufacturing (RPM) – – Clinical trial to study autologous CD19-specific CAR-T using RPM technology designed to reduce cost and simplify production for infusion the day after gene transfer – BOSTON , Dec.
View HTML
Toggle Summary Ziopharm Comments on Consent Solicitation Results
Jaime Vieser and Holger Weis Elected to Board of Directors BOSTON , Dec. 16, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today issued a statement in connection with the consent solicitation (the “Consent Solicitation”) initiated by WaterMill Asset
View HTML
Toggle Summary Ziopharm Oncology Announces Chief Financial Officer to Step Down
BOSTON , Dec. 14, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today announced that Satyavrat “Sath” Shukla, CFA, Chief Financial Officer, has informed the Company of his intention to step down from the role effective December 31, 2020 to pursue
View HTML
Toggle Summary Ziopharm Comments on Delay of WaterMill’s Stated Consent Deadline
Ziopharm Recommends Shareholders Return the GREEN Consent Revocation Card BOSTON , Dec. 11, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today issued a statement in connection with the consent solicitation (the “Consent Solicitation”) initiated by
View HTML
Toggle Summary Egan-Jones Recommends Against Electing Dissident’s Full Slate of Nominees to Ziopharm Board
Recommends A gainst E lecting WaterMill Nominee Jaime Vieser Ziopharm Continues to Recommend that Shareholders Support Company’s Strong Progress by Return ing the GREEN Consent Revocation Card BOSTON , Dec. 10, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc.
View HTML
Toggle Summary Ziopharm Details Actions in Response to Shareholder Feedback
Has Held Several Discussions with WaterMill   to Reach an Amicable Resolution to Consent Solicitation Board Accepts Resignation of Director Elan Ezickson Reiterates Concerns About Professional   Past of WaterMill Nominee   Holger Weis BOSTON , Dec. 04, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology ,
View HTML
Toggle Summary Ziopharm Comments on Institutional Shareholder Services’ Recommendation to Reject WaterMill’s Attempt to Remove Half of Ziopharm’s Board of Directors
ISS Acknowledges Ziopharm’s Outperformance of its Peer Group During Chairman Scott Tarriff’s Tenure Court Filings R aise Concerns About Professional Past of WaterMill Nominee Holger Weis Ziopharm Recommends Shareholders Return the GREEN Consent Revocation Card BOSTON , Nov.
View HTML